Literature DB >> 6601823

Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS).

R C Gallo, P S Sarin, E P Gelmann, M Robert-Guroff, E Richardson, V S Kalyanaraman, D Mann, G D Sidhu, R E Stahl, S Zolla-Pazner, J Leibowitch, M Popovic.   

Abstract

Several isolates of a human type-C retrovirus belonging to one group, known as human T-cell leukemia virus (HTLV), have previously been obtained from patients with adult T-cell leukemia or lymphoma. The T-cell tropism of HTLV and its prevalence in the Caribbean basin prompted a search for it in patients with the epidemic T-cell immune deficiency disorder known as AIDS. Peripheral blood lymphocytes from one patient in the United States and two in France were cultured with T-cell growth factor (TCGF) an shown to express HTLV antigens. Virus from the U.S. patient was isolated and characterized and shown to be related to HTLV subgroup I. The virus was also transmitted into normal human T cells from umbilical cord blood of a newborn. Whether or not HTLV-I or other retroviruses of this family with T-cell tropism cause AIDS, it is possible that patients from whom the virus can be isolated can also transmit it to others. If the target cell of AIDS is the mature T cell as suspected, the methods used in these studies may prove useful for the long-term growth of these cells and for the identification of antigens specific for the etiological agent of AIDS.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6601823     DOI: 10.1126/science.6601823

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  213 in total

1.  Anti-HIV-1 efficacy of extracts from medicinal plants.

Authors:  Su-A Lee; Seong-Karp Hong; Chang-Il Suh; Mi-Hwa Oh; Jeong-Ho Park; Byoung-Wook Choi; Seung-Won Park; Soon-Young Paik
Journal:  J Microbiol       Date:  2010-05-01       Impact factor: 3.422

Review 2.  Translating insights from persistent LCMV infection into anti-HIV immunity.

Authors:  Elizabeth B Wilson; David G Brooks
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

Review 3.  Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.

Authors:  Arun K Ghosh; Heather L Osswald; Gary Prato
Journal:  J Med Chem       Date:  2016-01-22       Impact factor: 7.446

Review 4.  [HIV-related symptoms].

Authors:  A Potthoff; N H Brockmeyer
Journal:  Urologe A       Date:  2006-12       Impact factor: 0.639

5.  Experimental Adaptive Evolution of Simian Immunodeficiency Virus SIVcpz to Pandemic Human Immunodeficiency Virus Type 1 by Using a Humanized Mouse Model.

Authors:  Kei Sato; Naoko Misawa; Junko S Takeuchi; Tomoko Kobayashi; Taisuke Izumi; Hirofumi Aso; Shumpei Nagaoka; Keisuke Yamamoto; Izumi Kimura; Yoriyuki Konno; Yusuke Nakano; Yoshio Koyanagi
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

6.  Effects of Hinge-region Natural Polymorphisms on Human Immunodeficiency Virus-Type 1 Protease Structure, Dynamics, and Drug Pressure Evolution.

Authors:  Zhanglong Liu; Xi Huang; Lingna Hu; Linh Pham; Katye M Poole; Yan Tang; Brian P Mahon; Wenxing Tang; Kunhua Li; Nathan E Goldfarb; Ben M Dunn; Robert McKenna; Gail E Fanucci
Journal:  J Biol Chem       Date:  2016-08-30       Impact factor: 5.157

7.  HIV-1 Vpr hijacks EDD-DYRK2-DDB1DCAF1 to disrupt centrosome homeostasis.

Authors:  Delowar Hossain; Jérémy A Ferreira Barbosa; Éric A Cohen; William Y Tsang
Journal:  J Biol Chem       Date:  2018-05-03       Impact factor: 5.157

Review 8.  HIV infection and the gastrointestinal immune system.

Authors:  J M Brenchley; D C Douek
Journal:  Mucosal Immunol       Date:  2008-01       Impact factor: 7.313

Review 9.  The global HIV epidemic: What the pathologist needs to know.

Authors:  Carlos Del Rio
Journal:  Semin Diagn Pathol       Date:  2017-05-19       Impact factor: 3.464

10.  Evaluation of p-F-Phe-m-bis-(2-chloroethyl)amino-L-Phe-Met-ethoxy HCl against transplantable and spontaneous murine neoplasia.

Authors:  M J Yagi; J G Bekesi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.